Baoxiang Technology (Shenzhen) Co., Ltd.

To evaluate the safety and tolerability of PT217 in subjects with advanced solid tumors, evaluate the occurrence of limiting toxicity of PT217 in advanced solid tumors through dose escalation, and determine the maximum tolerated dose (if reached) and the recommended dose for Phase II. To evaluate the pharmacokinetic characteristics, immunogenicity, cytokine levels and preliminary anti-tumor activity of PT217 in subjects with advanced solid tumors.

Evaluate the safety and tolerability of PT199 in subjects with advanced solid tumors, evaluate the occurrence of limiting toxicity of PT199 in advanced solid tumors through dose escalation, and determine the maximum tolerated dose (if reached) and the recommended expansion dose. Evaluate the pharmacokinetic and pharmacodynamic characteristics, immunogenicity, cytokines, and preliminary anti-tumor activity of PT199 in subjects with advanced solid tumors.

Evaluate the safety and tolerability of PT886 in subjects with advanced solid tumors, evaluate the occurrence of limiting toxicity of PT886 in advanced solid tumors through dose escalation, and determine the maximum tolerated dose (if reached) and the recommended dose for Phase II. Evaluate the pharmacokinetic characteristics, immunogenicity and preliminary anti-tumor activity of PT886 in subjects with advanced solid tumors.